AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own QuantumScape, you really have to believe solid-state lithium‑metal batteries can move from promising prototypes to reliable, scalable products before the company runs out of time and capital. The Honda joint research agreement fits directly into that story, because it focuses on the hard part: manufacturing processes, not just lab performance. In the near term, this adds another recognized automaker alongside Volkswagen’s PowerCo and may strengthen key catalysts around customer validation, pilot-line progress at the Eagle Line, and potential licensing traction. The stock’s sharp jump on the Honda news suggests the market sees this as more than routine collaboration, although it does not resolve core risks such as zero revenue, continued losses above US$400 million a year, and a rich valuation relative to book value.
However, one risk investors should not overlook is how long QuantumScape can fund this journey. Our expertly prepared valuation report on QuantumScape implies its share price may be too high.Explore 11 other fair value estimates on QuantumScape - why the stock might be a potential multi-bagger!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com